Natera Inc (NTRA)vsCharles Schwab Corp (SCHW)
NTRA
Natera Inc
$194.24
-11.64%
HEALTHCARE · Cap: $30.71B
SCHW
Charles Schwab Corp
$88.61
-0.64%
FINANCIAL SERVICES · Cap: $156.82B
Smart Verdict
WallStSmart Research — data-driven comparison
Charles Schwab Corp generates 976% more annual revenue ($24.80B vs $2.31B). SCHW leads profitability with a 38.0% profit margin vs -9.0%. SCHW earns a higher WallStSmart Score of 75/100 (B+).
NTRA
Avoid31
out of 100
Grade: F
SCHW
Strong Buy75
out of 100
Grade: B+
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Revenue surging 39.8% year-over-year
Keeps 38 of every $100 in revenue as profit
Strong operational efficiency at 49.2%
Conservative balance sheet, low leverage
Large-cap with strong market position
Attractively priced relative to earnings
15.8% revenue growth
Areas to Watch
Trading at 15.8x book value
0.0% earnings growth
ROE of -14.3% — below average capital efficiency
Currently unprofitable
No major concerns identified
Comparative Analysis Report
WallStSmart ResearchBull Case : NTRA
The strongest argument for NTRA centers on Revenue Growth. Revenue growth of 39.8% demonstrates continued momentum.
Bull Case : SCHW
The strongest argument for SCHW centers on Profit Margin, Operating Margin, Debt/Equity. Profitability is solid with margins at 38.0% and operating margin at 49.2%. Revenue growth of 15.8% demonstrates continued momentum.
Bear Case : NTRA
The primary concerns for NTRA are Price/Book, EPS Growth, Return on Equity.
Bear Case : SCHW
No major red flags identified for SCHW, but monitor valuation.
Key Dynamics to Monitor
NTRA profiles as a hypergrowth stock while SCHW is a growth play — different risk/reward profiles.
NTRA carries more volatility with a beta of 1.57 — expect wider price swings.
NTRA is growing revenue faster at 39.8% — sustainability is the question.
SCHW generates stronger free cash flow (7.2B), providing more financial flexibility.
Bottom Line
SCHW scores higher overall (75/100 vs 31/100), backed by strong 38.0% margins and 15.8% revenue growth. Both earn "Strong Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Natera Inc
HEALTHCARE · DIAGNOSTICS & RESEARCH · USA
Natera, Inc., a diagnostic company, develops and markets molecular testing services globally. The company is headquartered in San Carlos, California.
Charles Schwab Corp
FINANCIAL SERVICES · CAPITAL MARKETS · USA
The Charles Schwab Corporation is an American multinational financial services company. It offers banking, commercial banking, an electronic trading platform, and wealth management advisory services to both retail and institutional clients.
Visit Website →Compare with Other DIAGNOSTICS & RESEARCH Stocks
Want to dig deeper into these stocks?